Arbutus Biopharma Corporation (ABUS)

[mick]

$6.50 RATING, B.Riley Financial Keeps a Buy Rating on Arbutus Biopharma (ABUS)
Christine Brown- November 16, 2020, 10:26 AM EDTSHARE ON:
B.Riley Financial Keeps a Buy Rating on Arbutus Biopharma (ABUS)B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Arbutus Biopharma (ABUS) today and set a price target of $8.00. The company’s shares closed last Monday at $3.86.

According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 25.8% and a 52.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arbutus Biopharma with a $6.50 average price target, which is a 63.3% upside from current levels. In a report issued on November 10, Chardan Capital also reiterated a Buy rating on the stock with a $5.00 price target.